The Glaucoma Italian Pediatric Study (GIPSy): 3-Year Results

Luciano Quaranta; Elena Biagioli; Ivano Riva; Francesca Galli; Davide Poli; Eliana Rulli; Andreas Katsanos; Antonio Longo; Maurizio G Uva; Francesco Oddone; Valter Torri; Robert N Weinreb

doi:10.1097/IJG.0000000000001038

The Glaucoma Italian Pediatric Study (GIPSy): 3-Year Results

Luciano Quaranta, Elena Biagioli, Ivano Riva, Francesca Galli, Davide Poli, Eliana Rulli, Andreas Katsanos, Antonio Longo, Maurizio G Uva, Francesco Oddone, Valter Torri, Robert N Weinreb

Research output: Contribution to journal › Article › peer-review

Abstract

PURPOSE: To investigate the efficacy and safety of a treatment strategy with latanoprost and dorzolamide in primary pediatric glaucoma patients partially responsive to surgery.PATIENTS AND METHODS: Children with primary pediatric glaucoma with postsurgical intraocular pressure (IOP) between 22 and 26 mm Hg were eligible. At baseline, patients were administered latanoprost once daily. Depending on IOP reduction, patients were allocated to continuation of latanoprost monotherapy or addition of dorzolamide twice daily, or switch to dorzolamide monotherapy 3 times daily. Patients in the dorzolamide monotherapy group with IOP reduction

Original language	Italian
Pages (from-to)	856-863
Number of pages	8
Journal	Journal of Glaucoma
Volume	27
Issue number	10
DOIs	https://doi.org/10.1097/IJG.0000000000001038
Publication status	Published - Oct 2018

Access to Document

10.1097/IJG.0000000000001038

Cite this

@article{4f1717e184244f44a56f0a80d9b4cc3e,

title = "The Glaucoma Italian Pediatric Study (GIPSy): 3-Year Results",

abstract = "PURPOSE: To investigate the efficacy and safety of a treatment strategy with latanoprost and dorzolamide in primary pediatric glaucoma patients partially responsive to surgery.PATIENTS AND METHODS: Children with primary pediatric glaucoma with postsurgical intraocular pressure (IOP) between 22 and 26 mm Hg were eligible. At baseline, patients were administered latanoprost once daily. Depending on IOP reduction, patients were allocated to continuation of latanoprost monotherapy or addition of dorzolamide twice daily, or switch to dorzolamide monotherapy 3 times daily. Patients in the dorzolamide monotherapy group with IOP reduction ",

author = "Luciano Quaranta and Elena Biagioli and Ivano Riva and Francesca Galli and Davide Poli and Eliana Rulli and Andreas Katsanos and Antonio Longo and Uva, {Maurizio G} and Francesco Oddone and Valter Torri and Weinreb, {Robert N}",

year = "2018",

month = oct,

doi = "10.1097/IJG.0000000000001038",

language = "Italian",

volume = "27",

pages = "856--863",

journal = "Journal of Glaucoma",

issn = "1057-0829",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - The Glaucoma Italian Pediatric Study (GIPSy): 3-Year Results

AU - Quaranta, Luciano

AU - Biagioli, Elena

AU - Riva, Ivano

AU - Galli, Francesca

AU - Poli, Davide

AU - Rulli, Eliana

AU - Katsanos, Andreas

AU - Longo, Antonio

AU - Uva, Maurizio G

AU - Oddone, Francesco

AU - Torri, Valter

AU - Weinreb, Robert N

PY - 2018/10

Y1 - 2018/10

N2 - PURPOSE: To investigate the efficacy and safety of a treatment strategy with latanoprost and dorzolamide in primary pediatric glaucoma patients partially responsive to surgery.PATIENTS AND METHODS: Children with primary pediatric glaucoma with postsurgical intraocular pressure (IOP) between 22 and 26 mm Hg were eligible. At baseline, patients were administered latanoprost once daily. Depending on IOP reduction, patients were allocated to continuation of latanoprost monotherapy or addition of dorzolamide twice daily, or switch to dorzolamide monotherapy 3 times daily. Patients in the dorzolamide monotherapy group with IOP reduction

AB - PURPOSE: To investigate the efficacy and safety of a treatment strategy with latanoprost and dorzolamide in primary pediatric glaucoma patients partially responsive to surgery.PATIENTS AND METHODS: Children with primary pediatric glaucoma with postsurgical intraocular pressure (IOP) between 22 and 26 mm Hg were eligible. At baseline, patients were administered latanoprost once daily. Depending on IOP reduction, patients were allocated to continuation of latanoprost monotherapy or addition of dorzolamide twice daily, or switch to dorzolamide monotherapy 3 times daily. Patients in the dorzolamide monotherapy group with IOP reduction

U2 - 10.1097/IJG.0000000000001038

DO - 10.1097/IJG.0000000000001038

M3 - Articolo

SN - 1057-0829

VL - 27

SP - 856

EP - 863

JO - Journal of Glaucoma

JF - Journal of Glaucoma

IS - 10

ER -